AlphAIAlphAI — Financial news for AI agents
investing.comSEP 162 min read$VTRS

Piper Sandler raises Viatris stock price target on patch growth

Piper Sandler raised its price target for Viatris (VTRS) to $13.00, citing growth in its estradiol patch business and upcoming Phase III readouts. The stock is up 80% over the past year, trading at $16.65. Viatris reported better-than-expected Q2 2026 earnings and revenue, raising its full-year guidance. Piper Sandler maintains a Neutral rating, noting risks tied to biosimilars and clinical trial outcomes.

Original reporting
investing.com
Published Sep 16, 2026, 1:17 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 16, 2026, 7:59 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$VTRS
Bullish
high confidence
Mentioned
$VTRS
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$VTRSBullishMed
01

Why it matters

The price target raise and earnings beat could attract short-term buying, but valuation remains stretched.

02

Market read

Earnings beat and analyst upgrade provide fresh, actionable information for traders focusing on healthcare equities.

03

What to watch

Risks from China exposure, supply disruptions, and competition could offset earnings momentum.

Relevance 7/10Novelty 7/10Timing: Monday

Background

Piper Sandler's analyst note highlights Viatris' estradiol patch growth and upcoming Phase III readouts.

Company-level read

Ticker impact

$VTRSBullishHigh confidence
Context

Piper Sandler raised its price target on Viatris to $13 and reported Q2 2026 earnings beat with $0.69 EPS and $3.76B revenue.

Expected impact

Potential modest upside as target remains below current price, but earnings beat may narrow discount.

Evidence & confidence

Price target increase and better-than-expected results provide a fresh catalyst for traders.

Market effects

Sector

Positive signal for generic/pharma sector as earnings beat may lift peers.

Regional

U.S. market may see modest buying pressure in healthcare stocks.

Global

Limited; primarily affects U.S. listed pharma companies.

Counterpoint

What could challenge this read

Target remains well below current price; the upgrade may be premature if pipeline risks materialize.

Key entities

  • Company
    Viatris Inc.

    Generic and branded pharmaceutical manufacturer.

  • Analyst Firm
    Piper Sandler

    Equity research firm that raised the price target.

Read at source← All news

Related articles

SEP 19
$VTRSMedAI 8/10

Viatris (VTRS) Gains Japan WAKIX Approval As Fair Value Still Sits Higher

Viatris (VTRS) received Japanese approval for WAKIX, expanding its market. The stock is up 36% YTD and 77% over 1 year, closing at $16.95. Analysts estimate a fair value of $18.50, suggesting an 8% undervaluation. The company expects long-term growth from aging populations and chronic disease prevalence, but faces risks from generic price pressure and integration costs.

simplywall.st2 min
SEP 16
$VTRSHighAI 9/10

Viatris Announces Approval of WAKIX® (Pitolisant) in Japan, a First-in-Class Treatment for Narcolepsy and Excessive Daytime Sleepiness Associated With Obstructive Sleep Apnea Syndrome

Viatris Inc. (VTRS) received approval in Japan for WAKIX® (pitolisant) to treat narcolepsy and excessive daytime sleepiness in obstructive sleep apnea syndrome. This is the first histamine H3 receptor antagonist/inverse agonist approved for these conditions in Japan, addressing a high unmet medical need. The approval was supported by clinical trial data.

prnewswire.com2 min
SEP 14
$VTRSLow

Viatris names Kim Sun-A head of Japan-Korea cluster

Viatris Korea appointed Kim Sun-A to lead its new Japan-Korea cluster, overseeing strategy and collaboration between the regions. She retains her role as president of Viatris Japan. The move aims to boost cooperation between the countries' operations. Bill Schuster remains president of Viatris Korea, managing its local operations.

koreabiomed.com2 min
SEP 12
$VTRSLowAI 8/10

Nightly Eye Drop Tested for Night Driving Glare Improved Dim-Light Vision in One in Five Adults in Trial

A phase 3 trial of 0.75% phentolamine eye drops by Opus Genetics and Viatris showed 21% of adults with night vision issues improved on a dim-light eye chart after 15 days, compared to 3% on placebo. The drop, not yet FDA-approved for night vision, aims to reduce glare and halos. Results were published in the American Journal of Ophthalmology. A confirmatory trial is expected in 2026.

medicaldaily.com3 min
AUG 13
$VTRSMedAI 8/10

Viatris (VTRS) Q2 2026 Earnings Call Transcript

Viatris (VTRS) reported Q2 2026 revenue of $3.8B, up 3.5% operationally, with adjusted EBITDA of $1.2B and adjusted EPS of $0.69. Management raised 2026 guidance for revenue ($14.55B-$14.95B), adjusted EBITDA ($4.3B-$4.5B) and adjusted EPS ($2.45-$2.59). It also cited Nashik supply disruptions and FDA approval for its Gwyn Lo patch.

fool.com7 min